(Q36490622)

14 August 2017

1 reference

title

Conventional cytogenetics and FISH in the detection of BCR/ABL fusion in chronic myeloid leukemia (CML). (English)

1 reference

14 August 2017

main subject

chronic myeloid leukemia

0 references

author name string

Hon Fong L Mark

series ordinal

1

1 reference

14 August 2017

Robert A Sokolic

series ordinal

2

1 reference

14 August 2017

Yvonne Mark

series ordinal

3

1 reference

14 August 2017

publication date

26 May 2006

1 reference

Experimental and Molecular Pathology

14 August 2017

published in

1 reference

14 August 2017

volume

81

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

1-7

1 reference

Frequency of clonal B lymphocytes in chronic myelogenous leukemia evaluated by fluorescence in situ hybridization

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Philadelphia chromosome positive blood B lymphocytes in chronic myelocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Complex translocations of the Ph chromosome and Ph negative CML arise from similar mechanisms, as evidenced by FISH analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Imatinib therapy in chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

7 January 2021

Trisomy 10 in leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Accelerated and blastic phases of chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Fluorescence in situ hybridization characterization of different cryptic BCR-ABL rearrangements in chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Variant Ph translocations in chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Fluorescent in situ hybridization for identifying cytogenetic abnormalities in inadequate and suboptimal specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Fluorescence in situ hybridization analysis of single-cell trisomies for determination of clonality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

A multimodal approach in the diagnosis of patients with hematopoietic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Chronic myelogenous leukemia and myeloproliferative disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

7 January 2021

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Discordant detection of monosomy 7 by GTG-banding and FISH in a patient with Shwachman-Diamond syndrome without evidence of myelodysplastic syndrome or acute myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

The World Health Organization (WHO) classification of the myeloid neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Distinguishing between proliferating nodal lymphoid blasts in chronic myelogenous leukemia and non-Hodgkin lymphoma: report of three cases and detection of a bcr/abl fusion signal by single-cell analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

A fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.03.004

10.1016/J.YEXMP.2006.03.004

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference